<i>MET</i> Amplification Leads to Gefitinib Resistance in Lung Cancer by Activating ERBB3 Signaling
2007 · Science · 4,427 citations
https://doi.org/10.1126/science.1141478
T
Tony Mok
Claim or correct this author profile
Claim this profile or suggest corrections to the name, affiliation, bio, photo, or paper titles. Approved changes appear as verified CitedEvidence overlays.
1.1K
Papers
106.2K
Citations
131
h-index
487
i10-index
Tony Mok is an academic researcher from Department of Health. The author has contributed to research in topics: Lung Cancer Treatments and Mutations & Lung Cancer Research Studies & Colorectal Cancer Treatments and Studies. The author has an h-index of 131, co-authored 922 publications.
ORCID: 0000-0002-8251-0551Papers by this author
worksFirst-Line Atezolizumab plus Chemotherapy in Extensive-Stage Small-Cell Lung Cancer
2018 · New England Journal of Medicine · 3,395 citations
https://doi.org/10.1056/nejmoa1809064
Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial
2019 · The Lancet · 3,270 citations
https://doi.org/10.1016/s0140-6736(18)32409-7
Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial
2019 · The Lancet · 3,270 citations
https://doi.org/10.1016/s0140-6736(18)32409-7
Osimertinib or Platinum–Pemetrexed in <i>EGFR</i> T790M–Positive Lung Cancer
2016 · New England Journal of Medicine · 3,231 citations
https://doi.org/10.1056/nejmoa1612674
Afatinib versus gefitinib as first-line treatment of patients with EGFR mutation-positive non-small-cell lung cancer (LUX-Lung 7): a phase 2B, open-label, randomised controlled trial
2016 · The Lancet Oncology · 1,143 citations
https://doi.org/10.1016/s1470-2045(16)30033-x
Research topics
topicsChat about Author
Papers
Chat
Click to start Chat